2021
Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation
Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal Of Hepatology 2021, 75: 1312-1322. PMID: 34333102, PMCID: PMC8604762, DOI: 10.1016/j.jhep.2021.07.021.Peer-Reviewed Original ResearchConceptsSevere hepatic dysfunctionBaseline FIB-4Acute liver injuryHepatic dysfunctionInhibitor-based treatmentHepatic decompensationFIB-4Liver injuryHigh riskDAA therapyHazard ratioAdvanced liver fibrosis/cirrhosisRisk of ALIProtease inhibitor-based regimensProtease inhibitor-based treatmentLiver fibrosis/cirrhosisInhibitor-based regimensHepatitis C infectionSevere liver dysfunctionFibrosis/cirrhosisInhibitor-based therapyAminotransferase elevationChronic HCVALT elevationC infection
2019
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Inflammatory Biomarkers in Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and HIV/HCV Coinfection
Hanberg JS, Freiberg MS, Goetz MB, Rodriguez-Barradas MC, Gibert C, Oursler KA, Justice AC, Tate JP. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Inflammatory Biomarkers in Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and HIV/HCV Coinfection. Open Forum Infectious Diseases 2019, 6: ofz347. PMID: 31660334, PMCID: PMC6786514, DOI: 10.1093/ofid/ofz347.Peer-Reviewed Original ResearchHuman immunodeficiency virusVACS Index 2.0Veterans Aging Cohort StudyAddition of NLRHepatic decompensationLymphocyte ratioHepatitis C virusInflammatory biomarkersImmunodeficiency virusHepatitis C virus statusHIV/HCV coinfectionC virus statusPrognostic inflammatory biomarkerSoluble CD-14Strong unadjusted associationsAging Cohort StudyBiomarkers of inflammationPoor health outcomesMortality risk indexHCV coinfectionAntiretroviral therapyCohort studyBiomarker cohortD-dimerPrognostic index
2017
Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection
Re V, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Hennessy S, Kostman JR, Lim JK, Goetz MB, Gross R, Justice AC, Roy JA. Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoepidemiology And Drug Safety 2017, 26: 1172-1181. PMID: 28722244, PMCID: PMC5624832, DOI: 10.1002/pds.4258.Peer-Reviewed Original ResearchConceptsHepatitis C virusHIV/HCV patientsHuman immunodeficiency virusHepatic decompensationAntiretroviral therapyHCV patientsCohort studyHazard ratioHIV/hepatitis C virus (HCV) coinfectionChronic hepatitis C virusHepatitis C virus coinfectionHIV-/HCV-coinfected patientsHIV/HCV coinfectionVeterans Aging Cohort StudyC virus coinfectionChronic hepatic injuryAging Cohort StudyRisk of deathToxic nucleoside analoguesMarginal structural modelsHCV coinfectionLiver decompensationART regimensDecompensation eventsHepatic injury
2015
Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients
Re V, Kallan MJ, Tate JP, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park LS, Dubrow R, Reddy KR, Kostman JR, Justice AC, Localio AR. Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients. Open Forum Infectious Diseases 2015, 2: ofv109. PMID: 26284259, PMCID: PMC4536329, DOI: 10.1093/ofid/ofv109.Peer-Reviewed Original ResearchEnd-stage liver diseaseHIV/HCV-coinfected patientsRisk of ESLDHIV/HCV patientsHuman immunodeficiency virusFIB-4Antiretroviral therapyESLD riskHCV patientsLaboratory variablesLiver diseaseHuman immunodeficiency virus/hepatitis C virus‐coinfected patientsHepatitis C virus-coinfected patientsLiver-related deathRetrospective cohort studyRisk factor modificationPlatelet ratio indexDecision curve analysisVeterans Health AdministrationHCV treatment decisionsHepatic decompensationHCV treatmentCohort studyCox regressionImmunodeficiency virusLiver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion
Butt AA, Yan P, Re V, Rimland D, Goetz MB, Leaf D, Freiberg MS, Klein MB, Justice AC, Sherman KE. Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion. JAMA Internal Medicine 2015, 175: 178-185. PMID: 25485735, PMCID: PMC5017246, DOI: 10.1001/jamainternmed.2014.6502.Peer-Reviewed Original ResearchConceptsDiagnosis of cirrhosisLiver fibrosis progressionHepatic decompensation eventsDevelopment of cirrhosisFibrosis progressionHCV controlHepatic decompensationDecompensation eventsLiver fibrosisNegative HCV antibody test resultPositive HCV RNA test resultLower mean body mass indexHCV antibody test resultHCV RNA test resultsNational Veterans Affairs databaseHepatitis C virus infectionMean body mass indexHigher serum aminotransferase levelsHCV Infected VeteransRNA test resultsC virus infectionFIB-4 scoreFibrosis-4 indexSerum aminotransferase levelsMonths of follow
2014
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.
Lo Re V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Annals Of Internal Medicine 2014, 160: 369-79. PMID: 24723077, PMCID: PMC4254786, DOI: 10.7326/m13-1829.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsAscitesBacterial InfectionsCarcinoma, HepatocellularCoinfectionEsophageal and Gastric VaricesFemaleGastrointestinal HemorrhageHepatitis C, ChronicHIVHIV InfectionsHumansIncidenceLiver NeoplasmsMaleMedication AdherenceMiddle AgedPeritonitisRetrospective StudiesRNA, ViralTreatment OutcomeViral LoadConceptsCo-infected patientsHepatitis C virusHepatic decompensationAntiretroviral-treated patientsCohort studyNonblack raceC virusHepatitis C virus-monoinfected patientsChronic hepatitis C virusHigh rateAntiretroviral therapy eraDetectable HCV RNAIncident hepatic decompensationBaseline hemoglobin levelRetrospective cohort studySpontaneous bacterial peritonitisAdvanced hepatic fibrosisAdvanced liver fibrosisVeterans Health AdministrationDiagnosis of ascitesRate of decompensationTherapy eraHIV RNAVariceal hemorrhageHCV RNA
2013
Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus–Coinfected Veterans
Anderson JP, Tchetgen E, Re V, Tate JP, Williams PL, Seage GR, Horsburgh CR, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Klein MB, Justice AC. Antiretroviral Therapy Reduces the Rate of Hepatic Decompensation Among HIV- and Hepatitis C Virus–Coinfected Veterans. Clinical Infectious Diseases 2013, 58: 719-727. PMID: 24285848, PMCID: PMC3922212, DOI: 10.1093/cid/cit779.Peer-Reviewed Original ResearchConceptsHepatitis C virusInitiation of ARTAntiretroviral therapyHepatic decompensationHazard ratioVeterans Aging Cohort Study Virtual CohortHIV/HCV-coinfected patientsHuman immunodeficiency virus (HIV) coinfectionEnd-stage liver diseaseHepatic decompensation eventsIncident hepatic decompensationLiver disease outcomesCombination antiretroviral therapyImmunodeficiency virus coinfectionHospital discharge diagnosisSpontaneous bacterial peritonitisCopies/mLMarginal structural modelsART initiationART regimenDecompensation eventsHIV RNAVariceal hemorrhageBacterial peritonitisLiver failure
2011
Validity of diagnostic codes and liver‐related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study
Re V, Lim JK, Goetz MB, Tate J, Bathulapalli H, Klein MB, Rimland D, Rodriguez‐Barradas M, Butt AA, Gibert CL, Brown ST, Kidwai F, Brandt C, Dorey‐Stein Z, Reddy KR, Justice AC. Validity of diagnostic codes and liver‐related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiology And Drug Safety 2011, 20: 689-699. PMID: 21626605, PMCID: PMC3131229, DOI: 10.1002/pds.2148.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyHepatic decompensation eventsPositive predictive valueHigh positive predictive valueLaboratory abnormalitiesAging Cohort StudyDecompensation eventsDiagnostic codesCohort studyHepatic decompensationVariceal hemorrhageOutpatient diagnostic codesChronic liver diseaseSpontaneous bacterial peritonitisImpact of medicationLiver dysfunctionBacterial peritonitisLiver diseaseMedical recordsOutpatient codesPredictive valueNatural historyAbnormalitiesEpidemiologic researchPatients